Cases
Diplomat Pharmacy, Inc. (NYSE : DPLO)
Securities Class Action
Overview
Overview
- Date:
- 11/11/2016
- Company Name:
- Diplomat Pharmacy, Inc.
- Stock Symbol:
- DPLO
- Class Period:
- FROM 10/6/2014 TO 11/2/2016
- Status:
- Closed/Complete
- Court:
- U.S. District Court: Eastern District of Michigan
NEW YORK, November 11, 2016 – Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the United States District Court for the Michigan Eastern District on behalf of all persons or entities who acquired Diplomat Pharmacy, Inc. (NYSE: DPLO) securities between October 6, 2014 to November 2, 2016 (the “Class Period”).
The complaint alleges that throughout the Class Period, Defendants made false and misleading statements and/or failed to disclose that: (1) Diplomat lacked sufficient internal controls over its financial reporting; (2) consequently, Diplomat could not adequately calculate DIR fees; (3) Diplomat's hepatitis C segment was not performing as formerly released to shareholders; (4) as a result, Diplomat had exaggerated its 2016's full-year guidance; (5) and accordingly, Defendants' statements regarding its business, operations, and prospects, were false and misleading and/or lacked a reasonable basis. Following this news Diplomat stock dropped in value.
If you acquired Diplomat securities during the Class Period, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters please contact Melissa A. Fortunato, Esq. by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period, Defendants made false and misleading statements and/or failed to disclose that: (1) Diplomat lacked sufficient internal controls over its financial reporting; (2) consequently, Diplomat could not adequately calculate DIR fees; (3) Diplomat's hepatitis C segment was not performing as formerly released to shareholders; (4) as a result, Diplomat had exaggerated its 2016's full-year guidance; (5) and accordingly, Defendants' statements regarding its business, operations, and prospects, were false and misleading and/or lacked a reasonable basis. Following this news Diplomat stock dropped in value.
If you acquired Diplomat securities during the Class Period, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters please contact Melissa A. Fortunato, Esq. by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.